The Safety Profile of Ibopamine, an Alternative Substance for Treatment of Chronic Heart Failure
| Autor: | H. Just, C. Holubarsch |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Drug
medicine.medical_specialty Cardiotonic Agents Vasodilator Agents medicine.medical_treatment media_common.quotation_subject Dopamine agonist Plasma renin activity Electrocardiography chemistry.chemical_compound Oral administration Internal medicine Ibopamine medicine Humans Pharmacology (medical) media_common Heart Failure Chemotherapy Aldosterone business.industry Hemodynamics Water-Electrolyte Balance medicine.disease Deoxyepinephrine Endocrinology chemistry Heart failure Cardiology Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiology. 77:1-8 |
| ISSN: | 1421-9751 0008-6312 |
| Popis: | Before a new drug can be recommended for treatment of chronic heart failure, efficacy and safety have to be fulfilled. In this paper, the safety aspect of ibopamine, a congener of dopamine, is investigated by reviewing the available reports on this drug. A trend towards reduced mortality was found for patients with chronic heart failure during long-term treatment. No change in the potassium serum concentration has been found, whereas the plasma renin activity, plasma norepinephrine levels and the aldosterone secretion were decreased. It is concluded that ibopamine is a safe drug which may become an interesting alternative or additive therapy for patients with chronic heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|